TESAMORELIN VS IPA / CJC-1295
Both are GHRH-axis research compounds, but tesamorelin is FDA-approved (Egrifta®) while CJC-1295 No DAC is research-use only. Tesamorelin is a stabilized GHRH(1-44) · the full natural 44-aa hormone sequence. CJC-1295 No DAC is a GHRH(1-29) analog · the shorter active fragment with stabilizing substitutions. The IPA/CJC-1295 pair adds ghrelin-receptor agonism via ipamorelin.
SIDE BY SIDE
WHICH IS BETTER · BY GOAL
Tesamorelin has the only FDA-approved label for visceral-adipose reduction. Pooled Phase 3 -15.4% VAT at 26 weeks (Falutz 2010 PMID 20554713).
IPA/CJC-1295 combines GHRH-receptor + ghrelin-receptor stimulation, producing larger GH pulses via dual-pathway activation. Tesamorelin engages GHRH-R only.
Tesamorelin (Egrifta) is expensive at the branded human-prescription level. Research-grade CJC-1295 + ipamorelin is significantly cheaper for laboratory characterization.
STACKING NOTE
Tesamorelin + IPA/CJC-1295 = the GH-Axis Trifecta stack · three complementary upstream regulators of the GH pulse. Combining multiple GH-axis agonists is not supported by published research; the stack is a reference framing rather than a clinical protocol.
SOURCED FROM GIGACOMPOUNDS
Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

